Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
SAMPLE:
Patients must have histologically-confirmed diagnosis of stage IIIB or IV NSCLC, with prior treatment with Erlotinib. In the phase I study the upper expected number of patients will be eighteen. In the phase II thirty two eligible patients will be included in the study. The enrollment period will be approximately 1.5 years. All patients will be treated with Erlotinib and Vorinostat regimen. Participating hospitals will be those of the Spanish Lung Cancer Group (SLCG).
For the phase I portion, there will be 3 sites: Dr. Noemi Reguart and Dr. Rafael Rosell, Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona (Barcelona, Spain), Dr. Felip Cardenal, Institut Catalan d'Oncologia. Centre Sanitari i Universitari de Bellvitge (CSUB), Hospitalet de Llobregat (Barcelona, Spain) and Dr. Lola Isla, Hospital Clinico Lozano Blesa, (Zaragoza, Spain) For the phase II portion, 10 hospitals (adding 7 to the first 3) from the Spanish Lung Cancer Group (SLCG) will be involved. Hospitals will be included during phase I study.
OBJECTIVES AND HYPOTHESES Primary Phase I
(1) To determine the MTD of oral vorinostat in combination with erlotinib and to ensure that this treatment is sufficiently safe and tolerable to permit further study.
Phase II (1) To determine the percentage of patients free of progression at 12 weeks. Hypothesis: We considered that treatment was effective if we obtained a percentage of patients free of progression at 12 weeks higher than 60%.
Secondary
(1) To determine the CBR (clinical benefit rate), response rate, time to progression, time to response, response duration, and progression free survival in patients treated with vorinostat and erlotinib in combination.
Hypothesis: CBR should be of at least 25% and it will include stable disease for at least 3 months and objective RECIST response for at least 4 weeks.
Exploratory endpoints
Molecular analysis:
Main Objective: analysis of EGFR mutations (in exons 19, 20 and 21) in serum samples at baseline (before treatment), at three months of treatment and at the end of the treatment.
Secondary Objectives: retrospective analysis of molecular markers potentially related to drug sensitivity such as E-catherin protein expression, thioredoxin serum levels; Hsp70; methylation of 14-3-3r and CHFR.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic
-
Barcelona, Spain, 08025
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Spain, 08028
- Instituto Universitario Dexeus
-
Barcelona, Spain, 08907
- Institut Catalá d'Oncologia, Centre Sanitari i Universitari de Bellvitge (CSUB)
-
Barcelona, Spain, 08916
- Institut Catalá d'Oncología, Hospital Germans Trias i Pujol
-
Madrid, Spain, 28046
- Hospital La Paz
-
Valencia, Spain, 46010
- Hospital Clínico Universitario de Valencia
-
Zaragoza, Spain, 50009
- Hospital Clinico Lozano Blesa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed NSCLC
- Diagnosis of advanced stage IIIB with pleural effusion or IV NSCLC
- Previous disease progression after >= 3 months treatment with Erlotinib. Must tolerate erlotinib dose of 150 mg daily during the prior month.
- Have demonstrated mutations at epidermal growth factor receptor (EGFR) at Exon 19 or Exon 21 (Exon 19 mutations characterized by in-frame deletions (747-750), and Exon 21 mutations resulting in L858R substitutions).
- At least 18 years old.
- Measurable disease as defined by the presence of at least one lesion that can be accurately measured in at least one dimension using RECIST guidelines.
- At least 4 weeks from any prior major surgery or radiation therapy and have adequately recovered from the toxicities and/or complications
- ECOG performance status 0 to 2
- Adequate bone marrow function without the current use of colony stimulating factors.
- Adequate coagulation function.
- Adequate liver function
- Adequate renal function
- Non-sterilized premenopausal female, pregnancy test must be performed and patient must agree to use barrier methods of contraception. Male patients must agree to use an adequate method of contraception.
- Available for periodic blood sample analyses, study related assessments 15.Patient has the ability to understand and willingness to sign the informed consent form.
16.Patient is able to read, understand, and complete the study questionnaires.
Exclusion Criteria:
- Patient has been treated with any investigational agent for any indication within 4 weeks of study treatment.
- Patient previously treated with Vorinostat or any other HDAC inhibitor for any indication in the previous 30 days.
- Patient has history of hypersensitivity or intolerance to Erlotinib.
- Patient has an active infection or has received intravenous antibiotic, antiviral or antifungal medications with 2 weeks
- Patient with symptomatic central nervous system metastases with or without corticosteroids treatment.
- Inability to take and/or tolerate oral medications.
- Patient has known active hepatitis B or C infection,(HIV) HIV-related malignancy.
- Pregnant or breastfeeding.
- Patient with a history of gastrointestinal disease, surgery
- Patient with uncontrolled undercurrent illness or circumstances that could limit compliance with the study.
- History of malignancy except for inactive non-melanoma skin cancer and/or in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 5 years prior to study enrollment.
- Patient has had prescription or non-prescription drugs or other products known to influence CYP3A4 that cannot be discontinued prior to day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Vorinostat plus erlotinib
|
Phase I: Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily Phase II: Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression Free Survival Rate at 12 Weeks
Time Frame: From date of first day of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 weeks
|
Progression Free Survival was defined as time from first treatment until progression or death from any cause.
|
From date of first day of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 weeks
|
|
Maximum Tolerated Dose (MTD) of Oral Vorinostat Phase I
Time Frame: Up to 24 weeks for each dosing cohort
|
In the phase I, a classic 3 + 3 dose escalation method with 3 patients treated initially at each dose level was used.
MTD was determined by testing on dose escalation cohorts: continuous full dose of erlotinib 150 mg orally (p.o.) in a daily administration(QD) and escalating doses of vorinostat p.o. at three dose levels:300 mg QD 7 days every 21 days, 400 mg QD 7 days every 21 days,and 400 mg QD, 7 days every other week.
MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in less than or equal to 1 in 6 patients.
DLTs were defined as any Vorinostat-related Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE 3.0) Grade 3 or 4 adverse events.
|
Up to 24 weeks for each dosing cohort
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: From the date of study inclusion until end of follow up, up to 36 months.
|
Overall survival was defined as time from study inclusion until death
|
From the date of study inclusion until end of follow up, up to 36 months.
|
|
Time to Progression
Time Frame: From the date of randomization until end of follow up, up to 36 months.
|
The time to progression has been defined as the time that elapses, in months, since the patient begins study treatment until the patient progresses or dies from the disease, the first thing that occurs.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
|
From the date of randomization until end of follow up, up to 36 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Teresa Moran, MD, Medical Oncology Service. Institut Catala d'Oncologia- ICO. Hospital Germans Trias i Pujol. Badalona - Barcelona (Spain)
- Study Chair: Dolores Isla, MD, Medical Oncology Service. Hospital Clinico Lozano Blesa. Zaragoza. Spain
- Study Chair: Felip Cardenal, MD, Institut Catala d'Oncologia. Centre Sanitari i Universitari de Bellvitge (CSUB). Hospitalet de Llobregat (Barcelona). Spain
- Study Chair: Bertomeu Massutti, MD, Medical Oncology Service. General Hospital. Alicante. Spain
- Study Chair: Rafael Rosell, MD, Medical Oncology Service. Institut Catala d'Oncologia- ICO. Hospital Germans Trias i Pujol. Badalona - Barcelona (Spain)
- Study Chair: Noemi Reguart, MD, Medical Oncology Service. Hospital Clinic - Barcelona (Spain)
- Principal Investigator: Amelia Insa, MD, Medical Oncology Service. Hospital Clínico Universitario - Valencia (Spain)
- Principal Investigator: Cinta Pallarés, MD, Medical Oncology Service. Hospital de la Santa Creu i Sant Pau - Barcelona (Spain)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Histone Deacetylase Inhibitors
- Erlotinib Hydrochloride
- Vorinostat
Other Study ID Numbers
- TARZO
- 2007-003646-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.